Clin Cancer Res. 2011 Nov 15;17(22):6955-7. doi: 10.1158/1078-0432.CCR-11-2302. Epub 2011 Nov 8.
The success of immunotherapy in Hodgkin lymphoma is hampered partly by limited expression of tumor-specific antigens in the malignant cells. One strategy to increase tumor immunogenicity may be to enhance the expression of Hodgkin lymphoma-specific antigens such as MAGE-A4 using epigenetic-modifying drugs in combination with cancer testis antigen-specific immunotherapy.
免疫疗法在霍奇金淋巴瘤中的成功受到恶性细胞中肿瘤特异性抗原表达有限的部分阻碍。一种增加肿瘤免疫原性的策略可能是使用表观遗传修饰药物联合癌症睾丸抗原特异性免疫疗法来增强霍奇金淋巴瘤特异性抗原(如 MAGE-A4)的表达。